Arbutus Biopharma Files 8-K
Ticker: ABUS · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, corporate-update
TL;DR
Arbutus Biopharma filed an 8-K on Jan 13, 2025, updating financials and operations.
AI Summary
Arbutus Biopharma Corporation filed an 8-K on January 13, 2025, reporting on its results of operations, financial condition, and other events. The filing also includes financial statements and exhibits. The company was formerly known as Tekmira Pharmaceuticals Corp.
Why It Matters
This 8-K filing provides an update on Arbutus Biopharma's financial status and operational events, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing providing standard corporate updates and financial information.
Key Players & Entities
- Arbutus Biopharma Corporation (company) — Registrant
- Tekmira Pharmaceuticals Corp (company) — Former company name
- January 13, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Arbutus Biopharma Corporation's results of operations and financial condition, as well as other events and financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on January 13, 2025.
What was Arbutus Biopharma Corporation's former name?
Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.
Where is Arbutus Biopharma Corporation's principal executive office located?
Arbutus Biopharma Corporation's principal executive office is located at 701 Veterans Circle, Warminster, Pennsylvania 18974.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 620 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-13 07:31:11
Filing Documents
- f8k_011325.htm (8-K) — 16KB
- exh_991.htm (EX-99.1) — 15KB
- exh_992.htm (EX-99.2) — 34KB
- exh992_01.jpg (GRAPHIC) — 72KB
- exh992_02.jpg (GRAPHIC) — 187KB
- exh992_03.jpg (GRAPHIC) — 123KB
- exh992_04.jpg (GRAPHIC) — 105KB
- exh992_05.jpg (GRAPHIC) — 128KB
- exh992_06.jpg (GRAPHIC) — 114KB
- exh992_07.jpg (GRAPHIC) — 85KB
- exh992_08.jpg (GRAPHIC) — 58KB
- exh992_09.jpg (GRAPHIC) — 127KB
- exh992_10.jpg (GRAPHIC) — 109KB
- exh992_11.jpg (GRAPHIC) — 121KB
- exh992_12.jpg (GRAPHIC) — 128KB
- exh992_13.jpg (GRAPHIC) — 97KB
- exh992_14.jpg (GRAPHIC) — 80KB
- exh992_15.jpg (GRAPHIC) — 60KB
- exh992_16.jpg (GRAPHIC) — 105KB
- exh992_17.jpg (GRAPHIC) — 92KB
- exh992_18.jpg (GRAPHIC) — 122KB
- exh992_19.jpg (GRAPHIC) — 89KB
- exh992_20.jpg (GRAPHIC) — 67KB
- exh992_21.jpg (GRAPHIC) — 124KB
- exh992_22.jpg (GRAPHIC) — 58KB
- 0001171843-25-000193.txt ( ) — 3381KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_011325_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 13, 2025, Arbutus Biopharma Corporation (the "Company") issued a press release (the "Press Release") announcing its 2025 corporate update and providing certain estimated financial information, including its estimated cash, cash equivalents and investments as of December 31, 2024 and its estimated 2024 cash burn. The amounts included in the Press Release are preliminary, have not been audited and are subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2024. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2024. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein. On January 13, 2025, the Company posted an updated corporate presentation on its website at www.arbutusbio.com (the "Corporate Presentation"), which included the Company's estimated cash, cash equivalents and investments as of December 31, 2024. A copy of the Corporate Presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.
01. Other Events
Item 8.01. Other Events. On January 13, 2025, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 hereto and is incorporated by reference herein. A copy of the Corporate Presentation is filed herewith as Exhibit 99.2 hereto and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release dated January 13, 2025 99.2 Corporate Presentation January 13, 2025 104 Cover page interactive data file (formatted as inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: January 13, 2025 By: /s/ David C. Hastings David C. Hastings Chief Financial Officer